medigraphic.com
ISSN 1817-5996 (Digital)

2014, Número 3

<< Anterior Siguiente >>

Rev Cub de Reu 2014; 16 (3)


Anti TNF-alfa como opción terapéutica en pacientes con superposición de artritis reumatoide, lupus eritematoso sistémico y hepatitis C

Ortega ECR, Saldarriaga RLM, Delgado QLA, Ríos GBBE

Idioma: Español
Referencias bibliográficas: 25
Paginas: 329-333
Archivo PDF: 452.05 Kb.


RESUMEN

La incidencia de infección crónica por el virus de hepatitis C en un paciente con enfermedad reumática es un desafío diagnóstico y terapéutico, ya que los medicamentos utilizados en el tratamiento de la artritis reumatoide y del lupus eritematoso sistémico son hepatotóxicos. Describimos el caso de una paciente de sexo femenino, con superposición de artritis reumatoide y lupus eritematoso sistémico con serología positiva para hepatitis C, quien recibió tratamiento con interferón alfa sin respuesta y en presencia de actividad de la enfermedad reumática fue refractaria al tratamiento, siendo utilizado Anti-TNF etanercept con resolución de la sintomatología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Villalba SR, Hernández MB, Sanmartí R. Cómo manejar al paciente con artritis reumatoide y serología virus de hepatitis B, hepatitis C, virus de la inmunodeficiencia humana. Reumatol Clin 2011;7(3):203-07.

  2. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. GISEA Group. Safety of anti-tumor necrosis factor-alfa therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944-49.

  3. Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis. 1987;(46):853-58

  4. Petri M, Orbai A, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677-86.

  5. Lormeau C, Falgarone G, Roulot D, Boissier MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine. 2006;73(6):633-38.

  6. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med. 1990;150(4):849-53.

  7. Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep. 2003;(5):200-04.

  8. Rosner I, Rozenbaum M, Toubi E, Kessel A, Naschitz JE, Zuckerman E. The case for hepatitis C arthritis. Semin Arthritis Rheum. 2004;33(6):375-87.

  9. Ramos-Casals M, Muñoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J, et al. HISPAMEC Study Group. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry) J Rheumatol. 2009;36(7):1442-48.

  10. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002;14:204-11.

  11. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am. 2009;35(1):111-23.

  12. Ferri C, Sebastiani M, Antonelli A, Colaci M, Manfredi A, Giuggioli D. Current treatment of hepatitis C associated rheumatic diseases. Arthritis Res Ther. 2012;14(3):215.

  13. Guilera M, Forns X, Torras X, Enriquez J, Coll S, Sola R, et al. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon treatment in chronic hepatitis C. J Hepatol. 2000;33(1):135-41.

  14. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.

  15. Biancone L, Del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G. Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology. 2002;122(2):593-4.

  16. Campbell S, Ghosh S. Infliximab treatment for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13(2):191-2.

  17. Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000;75(10):1093-98.

  18. Peterson J, Hsu F, Simkin P, Wener M. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62(11):1078-82.

  19. Jury E, D'Cruz D, Morrow W. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. Clin Pathol. 2001;54(5):340-47.

  20. Yang DH, Ho LJ, Lai JH. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol. 2014;20(11):2962-70

  21. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol. 2008;61(3):333-37.

  22. Ezzat WM, Raslan HM, Aly AA, Emara NA, El Menyawi MM, Edrees A. Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. Rheumatol Int. 2011;31(1):65-9.

  23. Palazzi C, Olivieri I, Cacciatore P, Pennese E, D'Amico E. Difficulties in the differential diagnosis between primitive rheumatic diseases and hepatitis C virus-related disorders. Clin Exp Rheumatol. 2005;23(1):2-6.

  24. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(4):1433-44.

  25. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2012;64(5):625-39.




2020     |     www.medigraphic.com